H.C. Wainwright Reaffirms Buy Rating on AngioDynamics (ANGO) After Strong Q1 Performance

Core Insights - AngioDynamics, Inc. (NASDAQ:ANGO) is highlighted as a small-cap stock with significant upside potential, supported by a Buy rating from H.C. Wainwright and a price target of $16 following strong fiscal Q1 2026 results [1][2]. Financial Performance - The company reported net sales of $75.7 million for Q1 2026, reflecting a year-over-year increase of 12.2%, primarily driven by a 26.1% rise in Med Tech revenue [2]. - Key products, AlphaVac and AngioVac, experienced substantial sales growth, with increases of over 50% and 37% respectively, contributing to a 91% stock return over the past year [2]. - Despite a net loss of $10.9 million, AngioDynamics achieved a positive adjusted EBITDA of $2.2 million [3]. - U.S. and international sales grew by 11.7% and 15.6%, respectively [3]. - The company raised its full-year guidance, projecting net sales between $308 million and $313 million, and adjusted EBITDA between $6.0 million and $10.0 million, while maintaining its gross margin outlook [3]. Company Overview - AngioDynamics is a global medical technology company that develops, produces, and markets devices for treating peripheral vascular disease, cancer, and surgical conditions, supporting both diagnostic and therapeutic procedures in U.S. and international healthcare markets [4].